Mineralys Therapeutics Inc’s recent filing unveils that its Chief Medical Officer Rodman David Malcom unloaded Company’s shares for reported $0.17 million on Jun 13 ’25. In the deal valued at $14.60 per share,11,366 shares were sold. As a result of this transaction, Rodman David Malcom now holds 101,651 shares worth roughly $1.4 million.
Then, Rodman David Malcom bought 11,366 shares, generating $165,931 in total proceeds.
Before that, Rodman David Malcom sold 11,366 shares. Mineralys Therapeutics Inc shares valued at $173,774 were divested by the Chief Medical Officer at a price of $15.29 per share. As a result of the transaction, Rodman David Malcom now holds 106,669 shares, worth roughly $1.47 million.
Jefferies initiated its Mineralys Therapeutics Inc [MLYS] rating to a Hold in a research note published on June 11, 2025; the price target was $15. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who began to cover the stock in early July with a ‘”a Buy”‘ rating. Goldman began covering MLYS with “Buy” recommendation on April 02, 2024. Wells Fargo started covering the stock on March 07, 2023. It rated MLYS as “an Overweight”.
Price Performance Review of MLYS
On Monday, Mineralys Therapeutics Inc [NASDAQ:MLYS] saw its stock jump 2.15%% to $13.77. Over the last five days, the stock has lost -3.84%. Mineralys Therapeutics Inc shares have risen nearly 16.79% since the year began. Nevertheless, the stocks have risen 11.86% over the past one year. While a 52-week high of $18.38 was reached on 03/19/25, a 52-week low of $8.24 was recorded on 02/25/25.
Levels Of Support And Resistance For MLYS Stock
The 24-hour chart illustrates a support level at 13.21, which if violated will result in even more drops to 12.65. On the upside, there is a resistance level at 14.07. A further resistance level may holdings at 14.37.
How much short interest is there in Mineralys Therapeutics Inc?
A steep rise in short interest was recorded in Mineralys Therapeutics Inc stocks on 2025-05-30, dropping by -0.27 million shares to a total of 6.16 million shares. Yahoo Finance data shows the prior-month short interest on 2025-04-30 was 6.43 million shares. There was a decline of -4.32%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on March 07, 2023 when Stifel began covering the stock and recommended ‘”a Buy”‘ rating along with a $45 price target.
